Kantonsspital St.Gallen
login

Omega-3 fatty acid supplementation in patients with chronic epilepsy: a randomized trial

Alan W C Yuen, Josemir W Sander, Dominique Flügel, Philip N Patsalos, Gail S Bell, Tony Johnson & Matthias J Koepp

abstract Animal studies and a preliminary clinical observation suggest that nutritional supplementation with long chain omega-3 fatty acids (omega-3 FAs) may be useful in the nonpharmacological treatment of patients with epilepsy. Omega-3 FAs increase seizure thresholds, and lower inflammatory mediators, which are increased in patients with epilepsy. In this first randomized, placebo-controlled parallel group trial of omega-3 FA supplementation with 1 g eicosapentaenoic acid (EPA) and 0.7 g docosahexaenoic acid (DHA) daily, 57 patients completed a 12-week double-blind phase. Seizure frequency was reduced over the first 6 weeks of treatment in the supplement group, but this effect was not sustained. The supplementation produced a significant increase in EPA and DHA concentrations and a reciprocal fall in arachidonic and linoleic acid concentrations. No change in serum AED concentrations was detected. Further studies are required to examine different omega-3 FA preparations, different doses, longer treatment duration, and larger sample sizes.
   
citation Yuen A W C, Sander J W, Flügel D, Patsalos P N, Bell G S, Johnson T, Koepp M J. Omega-3 fatty acid supplementation in patients with chronic epilepsy: a randomized trial. Epilepsy Behav 2005; 7:253-8.
   
type journal paper/review (English)
date of publishing 9-2005
journal title Epilepsy Behav (7/2)
ISSN print 1525-5050
pages 253-8
PubMed 16006194
DOI 10.1016/j.yebeh.2005.04.014